Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Hana Votavova, Zuzana Urbanova, David Kundrat, Michaela Dostalova Merkerova, Martin Vostry, Monika Hruba, Jaroslav Cermak, Monika Belickova
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2021-01-01
Cyfres:	Pharmaceuticals
Pynciau:	myelodysplastic syndrome iron chelation deferasirox molecular mechanisms
Mynediad Ar-lein:	https://www.mdpi.com/1424-8247/14/1/41
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!